Cargando…

Treatment of metastatic non-small cell lung cancer with NY-ESO-1 specific TCR engineered-T cells in a phase I clinical trial: A case report

This article presented a case of a human leukocyte antigen (HLA)-A2-positive patient with advanced cancer/testis antigen New York esophageal squamous cell carcinoma-1 (NY-ESO-1) expressing lung adenocarcinoma (LADC) who received adoptive cell therapy of T cell receptor engineered-T cells (TCR-T cell...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xia, Yan, Tian, Xiaopeng, Wang, Juntao, Qiao, Dongjuan, Liu, Xianhao, Xiao, Liang, Liang, Wenli, Ban, Dongcheng, Chu, Junjun, Yu, Jiaming, Wang, Rongfu, Tian, Geng, Wang, Mingjun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2018
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6256329/ https://www.ncbi.nlm.nih.gov/pubmed/30546433 http://dx.doi.org/10.3892/ol.2018.9534

Ejemplares similares

Current advances in cancer vaccines targeting NY-ESO-1 for solid cancer treatment
por: Zhou, Hong, et al.
Publicado: (2023)

Development of a TCR-like antibody and chimeric antigen receptor against NY-ESO-1/HLA-A2 for cancer immunotherapy
por: Liu, Xin, et al.
Publicado: (2022)

Biomarker correlates with response to NY-ESO-1 TCR T cells in patients with synovial sarcoma
por: Gyurdieva, Alexandra, et al.
Publicado: (2022)

An efficient method to identify virus-specific TCRs for TCR-T cell immunotherapy against virus-associated malignancies
por: Chen, Lei, et al.
Publicado: (2021)

Pushing forward in sarcoma with a new TCR targeting NY-ESO-1
por: Al-Marayaty, Rusul, et al.
Publicado: (2023)

Deep phenotypic characterization of NY-ESO TCR engineered T cells and tumor in patients with advanced myeloma
por: Davila, Eduardo, et al.
Publicado: (2015)

TCR-Engineered Lymphocytes Targeting NY-ESO-1: In Vitro Assessment of Cytotoxicity against Tumors
por: Alsalloum, Alaa, et al.
Publicado: (2023)

NY-ESO-1 specific TCR engineered T-cells mediate sustained antigen-specific antitumor effects in myeloma
por: Rapoport, Aaron P., et al.
Publicado: (2015)

Decitabine enhances targeting of AML cells by NY-ESO-1-specific TCR-T cells and promotes the maintenance of effector function and the memory phenotype
por: Kang, Synat, et al.
Publicado: (2022)

Synergistic Therapeutic Effects of Low Dose Decitabine and NY-ESO-1 Specific TCR-T Cells for the Colorectal Cancer With Microsatellite Stability
por: Yu, Ganjun, et al.
Publicado: (2022)

NY-ESO-1-specific redirected T cells with endogenous TCR knockdown mediate tumor response and cytokine release syndrome
por: Ishihara, Mikiya, et al.
Publicado: (2022)

Bi-specific TCR-anti CD3 redirected T-cell targeting of NY-ESO-1- and LAGE-1-positive tumors
por: McCormack, Emmet, et al.
Publicado: (2012)

Reprogramming of IL-12 secretion in the PDCD1 locus improves the anti-tumor activity of NY-ESO-1 TCR-T cells
por: Kim, Segi, et al.
Publicado: (2023)

Evaluation of Production Protocols for the Generation of NY-ESO-1-Specific T Cells
por: Gong, Wenjie, et al.
Publicado: (2021)

NY-ESO-1 as a potential immunotherapeutic target in renal cell carcinoma
por: Giesen, Eva, et al.
Publicado: (2014)

Human CLEC9A antibodies deliver NY-ESO-1 antigen to CD141(+) dendritic cells to activate naïve and memory NY-ESO-1-specific CD8(+) T cells
por: Masterman, Kelly-Anne, et al.
Publicado: (2020)

NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives
por: Thomas, Remy, et al.
Publicado: (2018)

Tumor-Infiltrating T Cells Correlate with NY-ESO-1-Specific Autoantibodies in Ovarian Cancer
por: Milne, Katy, et al.
Publicado: (2008)

NY-ESO-1 antigen-reactive T cell receptors exhibit diverse therapeutic capability
por: Sommermeyer, Daniel, et al.
Publicado: (2013)

Identification and assessment of TCR-T cells targeting an epitope conserved in SARS-CoV-2 variants for the treatment of COVID-19
por: Ma, Yipeng, et al.
Publicado: (2022)

Myeloid-derived suppressor cells infiltration in non-small-cell lung cancer tumor and MAGE-A4 and NY-ESO-1 expression
por: Hou, Zhenbo, et al.
Publicado: (2020)

Dose-dependent effects of NY-ESO-1 protein vaccine complexed with cholesteryl pullulan (CHP-NY-ESO-1) on immune responses and survival benefits of esophageal cancer patients
por: Kageyama, Shinichi, et al.
Publicado: (2013)

Increased NY-ESO-1 Expression and Reduced Infiltrating CD3+ T Cells in Cutaneous Melanoma
por: Giavina-Bianchi, Mara, et al.
Publicado: (2015)

NY-ESO-1- and survivin-specific T-cell responses in the peripheral blood from patients with glioma
por: Liu, Zhenjiang, et al.
Publicado: (2017)

Isolation and characterization of NY-ESO-1–specific T cell receptors restricted on various MHC molecules
por: Bethune, Michael T., et al.
Publicado: (2018)

MAGE-A3/4 and NY-ESO-1 antigens expression in metastatic esophageal squamous cell carcinoma
por: Bujas, T., et al.
Publicado: (2011)

Phase 1 clinical trial to assess safety and efficacy of NY-ESO-1-specific TCR T cells in HLA-A∗02:01 patients with advanced soft tissue sarcoma
por: Pan, Qiuzhong, et al.
Publicado: (2023)

Systemic and local immunity following adoptive transfer of NY-ESO-1 SPEAR T cells in synovial sarcoma
por: Ramachandran, Indu, et al.
Publicado: (2019)

NY-ESO-1 antibody as a novel tumour marker of gastric cancer
por: Fujiwara, S, et al.
Publicado: (2013)

NY-ESO-1 expression in sarcomas: A diagnostic marker and immunotherapy target
por: Lai, Jin-Ping, et al.
Publicado: (2012)

NY-ESO-1 expression in DCIS: A new predictor of good prognosis
por: Coombes, R. Charles, et al.
Publicado: (2017)

Involvement of NY-ESO-1 and MAGE-A4 in the pathogenesis of desmoid tumors
por: Hashimoto, Kazuhiko, et al.
Publicado: (2023)

Identification of Ny-Eso-1 Epitopes Presented by Human Histocompatibility Antigen (Hla)-Drb4*0101–0103 and Recognized by Cd4(+)T Lymphocytes of Patients with Ny-Eso-1–Expressing Melanoma
por: Jäger, Elke, et al.
Publicado: (2000)

HDAC Inhibition for Optimized Cellular Immunotherapy of NY-ESO-1-Positive Soft Tissue Sarcoma
por: Gong, Wenjie, et al.
Publicado: (2022)

Adoptive immunotherapy with engineered T cells expressing and HLA-A2 restricted affinity-enhanced TCR for LAGE-1 and NY-ESO-1 in patients with multiple myeloma following auto-SCT
por: Rapoport, Aaron P, et al.
Publicado: (2013)

Immune escape from NY-ESO-1-specific T cell therapy via loss of heterozygosity in the MHC
por: Klippel, Zandra K., et al.
Publicado: (2014)

Cancer stem-like cells with increased expression of NY-ESO-1 initiate breast cancer metastasis
por: Liu, Mai-Ying, et al.
Publicado: (2019)

Combination of autoantibodies against NY-ESO-1 and viral capsid antigen immunoglobulin A for improved detection of nasopharyngeal carcinoma
por: PENG, YU-HUI, et al.
Publicado: (2014)

First-in-human phase I clinical trial of the NY-ESO-1 protein cancer vaccine with NOD2 and TLR9 stimulants in patients with NY-ESO-1-expressing refractory solid tumors
por: Ishihara, Mikiya, et al.
Publicado: (2020)

Identification of NY-ESO-1(157–165) Specific Murine T Cell Receptors With Distinct Recognition Pattern for Tumor Immunotherapy
por: Zhang, Helin, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ujf3s1hp54s54s2e5rcji8cuqa